The preferred choice

KISQALI® is the preferred CDK4/6i in patients with
HR+/HER2– aBC^1-3

 

Image

 

NCCN guidance

KISQALI® is the only category 1** rated CDK4/6i in combination with both AI and fulvestrant²

 

Image

“In phase III randomised controlled trials, ribociclib [KISQALI®] + endocrine therapy has shown 
OS benefit in the first-line setting”2‡

 

OS achieved

KISQALI® Is the only CDK4/6i to achieve mOS in combination with an AI or fulvestrant in patients with HR+ HER2- mBC^3-6

 

Image

Image

*Other CDK4/6 is remain options based on patient comorbidities, tolerance, and availability.¹

**Based upon high-level evidence (≥1 randomised phase III trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the panel) that the intervention is appropriate.²

†Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the panel) that the intervention is appropriate.²

‡Compared with ET alone.

aBC, advanced breast cancer; ABC6/7, advanced breast cancer guidelines 6 and 7; AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; ESMO, European Society for Medical Oncology; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive;
MCBS, Magnitude of Clinical Benefit Scale; NCCN, National Comprehensive Cancer Network; OS, overall survival; PFS, progression-free survival; 1L, first-line; 2L, second-line.